Use of peg-filgrastim in severe chronic neutropenia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-003096-20-IT

Enrollment

Unknown

Registered

2005-07-22

Start date

2005-09-06

Completion date

Unknown

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe chronic neutropenia MedDRA version: 6.1 Level: SOC Classification code 10005329

Interventions

Trade Name: NEULASTA*6MG SC 1 SIR. Pharmaceutical Form: Solution for injection INN or Proposed INN: Pegfilgrastim Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 6-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026